Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Philipp Mayer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1957-1594; OpenAlex author ID A5047087649. Sources: OpenAlex.

Their work

Papers
21 (first author 4, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 6 papers · 2022: 1 paper · 2023: 3 papers · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 21

  1. Impact of sarcopenia and myosteatosis on early and long-term survival after surgical resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2026.04.007↗
  2. Aberrant Expression of A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13 (ADAMTS13) in Pancreatic Cancer Leads to Dichotomic Functions. Co-author DOI 10.1002/mco2.70462↗
  3. The radiomorphological appearance of the invasive margin in pancreatic cancer is associated with tumor budding. Co-author DOI 10.1007/s00423-024-03355-3↗
  4. Performance of different CT enhancement quantification methods as predictors of pancreatic cancer recurrence after upfront surgery. Last author DOI 10.1038/s41598-024-70441-3↗
  5. CT-based screening of sarcopenia and its role in cachexia syndrome in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0291185↗
  6. Evaluation of optimal acquisition delays of DECT iodine maps in pancreatic adenocarcinoma: A potential alternative to the Patlak model of CT perfusion. First author DOI 10.1016/j.heliyon.2023.e14726↗
  7. Evaluation and timing optimization of CT perfusion first pass analysis in comparison to maximum slope model in pancreatic adenocarcinoma. First author DOI 10.1038/s41598-023-37381-w↗
  8. IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Co-author DOI 10.1136/gutjnl-2022-327855↗
  9. Imaging features of intraductal tubulopapillary neoplasm of the pancreas and its differentiation from conventional pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-022-19517-6↗
  10. [The microarchitecture of pancreatic cancer from the point of view of the pathologist and the radiologist]. Co-author DOI 10.1007/s00292-021-00949-2↗
  11. Radiological evaluation of pancreatic cancer: What is the significance of arterial encasement >180° after neoadjuvant treatment? Co-author DOI 10.1016/j.ejrad.2021.109603↗
  12. Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2021.02.011↗
  13. Computed Tomography Perfusion Analysis of Pancreatic Adenocarcinoma using Deconvolution, Maximum Slope, and Patlak Methods - Evaluation of Diagnostic Accuracy … Co-author DOI 10.1055/a-1401-0333↗
  14. Assessment of tissue perfusion of pancreatic cancer as potential imaging biomarker by means of Intravoxel incoherent motion MRI and CT perfusion: correlation w… Co-author DOI 10.1186/s40644-021-00382-x↗
  15. Epithelial-to-Mesenchymal Transition in Pancreatic Cancer is associated with Restricted Water Diffusion in Diffusion-Weighted Magnetic Resonance Imaging. Co-author DOI 10.7150/jca.63633↗
  16. Diffusion Kurtosis Imaging-A Superior Approach to Assess Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12061656↗
  17. Restricted Water Diffusion in Diffusion-Weighted Magnetic Resonance Imaging in Pancreatic Cancer is Associated with Tumor Hypoxia. Co-author DOI 10.3390/cancers13010089↗
  18. The Microarchitecture of Pancreatic Cancer as Measured by Diffusion-Weighted Magnetic Resonance Imaging Is Altered by T Cells with a Tumor Promoting Th17 Pheno… Co-author DOI 10.3390/ijms21010346↗
  19. The Time to and Type of Pancreatic Cancer Recurrence after Surgical Resection: Is Prediction Possible? First author DOI 10.1016/j.acra.2018.07.025↗
  20. Interleukin 21 Receptor/Ligand Interaction Is Linked to Disease Progression in Pancreatic Cancer. First author DOI 10.3390/cells8091104↗
  21. Changes in the microarchitecture of the pancreatic cancer stroma are linked to neutrophil-dependent reprogramming of stellate cells and reflected by diffusion-… Co-author DOI 10.7150/thno.21089↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Miriam Klauß · 15 shared papers, 2018–2026 · strength 2.36
  2. Matthias M. Gaida · 15 shared papers, 2018–2025 · strength 2.22
  3. Thilo Hackert · 12 shared papers, 2018–2024 · strength 1.51
  4. Martin Loos · 4 shared papers, 2021–2026 · strength 0.83
  5. Wolfram Stiller · 4 shared papers, 2021–2023 · strength 0.72
  6. Stephan Skornitzke · 4 shared papers, 2021–2023 · strength 0.72
  7. Ekaterina Khristenko · 4 shared papers, 2020–2024 · strength 0.64
  8. Thomas P. Hank · 3 shared papers, 2021–2026 · strength 0.59
  9. Lars Grenacher · 3 shared papers, 2021–2023 · strength 0.46
  10. Markus Wolfgang Büchler · 2 shared papers, 2021–2026 · strength 0.41
  11. Stefan Heinrich · 2 shared papers, 2020–2025 · strength 0.33
  12. Anna‐Katharina König · 1 shared paper, 2026 · strength 0.28
  13. Ingmar Florin Rompen · 1 shared paper, 2026 · strength 0.28
  14. Mohammed Al‐Saeedi · 1 shared paper, 2026 · strength 0.28
  15. Niels Siegel · 1 shared paper, 2026 · strength 0.28
  16. Franziska L. Fritz · 2 shared papers, 2021 · strength 0.26
  17. Marco Koell · 2 shared papers, 2021 · strength 0.26
  18. Jörg Kaiser · 2 shared papers, 2020–2021 · strength 0.24
  19. Stephanie Allmang · 1 shared paper, 2025 · strength 0.23
  20. Vladimir Konstantinovich Lyadov · 1 shared paper, 2024 · strength 0.23
  21. Sherif A. Mohamed · 1 shared paper, 2024 · strength 0.20
  22. Alica Linnebacher · 2 shared papers, 2019–2020 · strength 0.20
  23. Neha Vats · 1 shared paper, 2023 · strength 0.19
  24. Jelena Djokić Kovač · 1 shared paper, 2019 · strength 0.14
  25. Willem Niesen · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.